ArticleAntimicrobial agents and chemotherapy2006
In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- High-depth whole genome sequencing of blood culture plates reveals evolutionary dynamics in cases of persistent bacteremia due to methicillin-resistantbioRxiv : the preprint server for biology · 2026Article
- Molecular Characterization of Rifampicin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- A Semisynthetic Kanglemycin Shows In Vivo Efficacy against High-Burden Rifampicin Resistant Pathogens.ACS infectious diseases · 2020Article
- Evolution of resistance mechanisms and biological characteristics of rifampicin-resistant Staphylococcus aureus strains selected in vitro.BMC microbiology · 2019Article
- Coinfection and Emergence of Rifamycin Resistance during a Recurrent Clostridium difficile Infection.Journal of clinical microbiology · 2016Article
- Rifamycins, Alone and in Combination.Cold Spring Harbor perspectives in medicine · 2016Review
- Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.Antimicrobial agents and chemotherapy · 2013Article
- Characterization of a rifampin-inactivating glycosyltransferase from a screen of environmental actinomycetes.Antimicrobial agents and chemotherapy · 2012Article
- Titanium-tethered vancomycin prevents resistance to rifampicin in Staphylococcus aureus in vitro.PloS one · 2012Article
- Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.Journal of clinical microbiology · 2011Article
- An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2010Article
- Future novel therapeutic agents for Clostridium difficile infection.Expert opinion on investigational drugs · 2010Review
- Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.Antimicrobial agents and chemotherapy · 2008Article
- Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease.World journal of gastroenterology · 2008Article
- Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective.Journal of clinical microbiology · 2008Article
- Efficacy of a novel rifamycin derivative, ABI-0043, against Staphylococcus aureus in an experimental model of foreign-body infection.Antimicrobial agents and chemotherapy · 2007Article
- Efficacy of novel rifamycin derivatives against rifamycin-sensitive and -resistant Staphylococcus aureus isolates in murine models of infection.Antimicrobial agents and chemotherapy · 2006Article
- Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes.Antimicrobial agents and chemotherapy · 2006Article
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We describe novel rifamycin derivatives (new chemical entities [NCEs]) that retain significant activity against a comprehensive collection of Staphylococcus aureus strains that are resistant to rifamycins. This collection of resistant strains contains 21 of the 26 known single-amino-acid alterations in RpoB, the target of rifamycins. Some NCEs also demonstrated a lower frequency of resistance development than rifampin and rifalazil in S. aureus as measured in a resistance emergence test. When assayed for activity against the strongest rifamycin-resistant mutants, several NCEs had MICs of 2 microg/ml, in contrast to MICs of rifampin and rifalazil, which were 512 microg/ml for the same strains. The properties of these NCEs therefore demonstrate a significant improvement over those of earlier rifamycins, which have been limited primarily to combination therapy due to resistance development, and suggest a potential use of these NCEs for monotherapy in several clinical indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.